Changing Paradigm of Immunooncology in Advanced Kidney Cancer: Nivolumab and Ipilimumab Combination in the First Line Therapy

Onkourologiya- Russian Federation

doi 10.17650/1726-9776-2019-15-1-125-130

Full Text

Abstract

Available in

Categories

Nuclear Medicine

Date

April 9, 2019

Authors

A. S. Olshanskaya

Publisher

Publishing House ABV Press

Related search

Cost-Effectiveness of Nivolumab in Combination With Ipilimumab in First-Line Treatment of Advanced Melanoma in Sweden

Value in Health

Occupational Health

English

Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma

Journal of Clinical Oncology

Cancer Research

English

Pcn190 - Cost-Effectiveness of Nivolumab + Ipilimumab in First-Line Treatment of Advanced or Metastatic Renal Cell Carcinoma in the Netherlands

Value in Health

Occupational Health

English

Paraneoplastic Hyperleucocytosis in a Melanoma Patient After Initiation of Ipilimumab and Nivolumab Combination Therapy

Journal for ImmunoTherapy of Cancer

Molecular Medicine

Cancer Research

English

OA11 First-Line Nivolumab + Ipilimumab in Asian Patients With Advanced NSCLC and High TMB (≥10 Mut/Mb): Results From CheckMate 227

Journal of Thoracic Oncology

Respiratory Medicine

English

Pcn184 - Cost-Effectiveness of Nivolumab Plus Ipilimumab in Advanced Melanoma

Value in Health

Occupational Health

English

P1.01-02 Long-Term Outcomes With First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up From CheckMate 012

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.04-29 Second or Third Line Nivolumab Versus First Line Nivolumab in Patients With Previously Treated Advanced Non Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-79 CheckMate 817: Safety of Flat-Dose Nivolumab Plus Weight-Based Ipilimumab for the First-Line (1L) Treatment of Advanced NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English